심장 POC 검사 기기 시장 : 제품, 디바이스 유형, 용도, 최종사용자별 - 세계 예측(2025-2030년)

The Cardiac POC Testing Devices Market was valued at USD 1.36 billion in 2023, expected to reach USD 1.52 billion in 2024, and is projected to grow at a CAGR of 12.36%, to USD 3.08 billion by 2030.

Cardiac Point-of-Care (POC) testing devices are portable medical diagnostic tools designed for quick and accurate assessment of cardiac markers directly at the site of patient care, rather than relying on centralized laboratory facilities. These devices are crucial in emergencies to provide rapid test results, assisting healthcare providers in making timely decisions, such as in cases of acute myocardial infarction. Their application extends across various settings, including hospitals, clinics, ambulatory care, and even home healthcare, thanks to their ease of use and non-reliance on specialized laboratories. Market growth is predominantly influenced by the rising prevalence of cardiovascular diseases, the increasing demand for rapid diagnostic solutions, and a worldwide trend towards decentralized patient management. Innovations in biomarker discovery and microfluidics are driving technological advancements in this sector, further expanding its application scope, and providing lucrative opportunities for new entrants and existing players alike. However, challenges remain due to stringent regulatory requirements, high device costs, and issues related to testing accuracy and reliability in non-laboratory settings. Regions with a burgeoning demand for healthcare infrastructure, such as Asia-Pacific and Latin America, present significant potential for market penetration and growth. Moreover, collaborative R&D efforts focusing on device miniaturization and connectivity enhancements, such as integration with health IT systems, offer avenues for differentiation and market leadership. Companies should capitalize on digital health trends by developing connected POC solutions that support telemedicine and remote monitoring, thus aligning with evolving patient care models. A key area for innovation lies in enhancing the reliability and breadth of the test panel available on POC devices, enabling comprehensive and more precise cardiac diagnostics. Continuous investment in AI-driven analytics for predictive healthcare can further position players favorably in the competitive landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac POC Testing Devices Market

The Cardiac POC Testing Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of cardiac disorders and rising geriatric population globally
  • Inclination toward the early detection and diagnosis of patients
  • Favorable government support for cardiac health
• Market Restraints
  • Potential risk of product recall in Cardiac POC testing devices
• Market Opportunities
  • Implementation of unique & new troponin-based test
  • Positive investment and startup ecosystem
• Market Challenges
  • Limitations and concerns associated with the accuracy of cardiac POC testing devices

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac POC Testing Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac POC Testing Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac POC Testing Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac POC Testing Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac POC Testing Devices Market

A detailed market share analysis in the Cardiac POC Testing Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac POC Testing Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac POC Testing Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac POC Testing Devices Market

A strategic analysis of the Cardiac POC Testing Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac POC Testing Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories, Inc., Alfa Scientific Designs, Inc., Bio-Rad Laboratories, Inc., Cipla Limited, Compagnie Merieux Alliance SAS, Danaher Corporation, F. Hoffmann-La Roche Ltd, Getein Biotech, Inc., Laboratory Corporation of America Holdings, LifeSign LLC, Medtronic plc, Merck KGaA, Nano-Ditech Corp., Nexus Dx, Inc., Nova Biomedical Corporation, Polymer Technology Systems, Inc. by Sinocare, Precision Biosensor, Inc., QuidelOrtho Corporation, Sekisui Chemical Co., Ltd., Siemens Healthineers AG, and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Cardiac POC Testing Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Cardiac Biomarker Test, Consumable & Accessories, and Devices. The Cardiac Biomarker Test is further studied across B-Type Natriuretic Peptide, Creatine Kinase-MB [CK-MB] Fraction, D-dimer Tests, Myoglobin Tests, and Troponin Tests. The Devices is further studied across Analyzers and Imaging & Monitoring Devices.
• Based on Device Type, market is studied across Bench-top POC Devices, Handheld POC Devices, and Wearable POC Devices.
• Based on Application, market is studied across Diagnostics & Screening and Monitoring.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Diagnostic Laboratories, Home Settings, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cardiac disorders and rising geriatric population globally
    • 5.1.1.2. Inclination toward the early detection and diagnosis of patients
    • 5.1.1.3. Favorable government support for cardiac health
  • 5.1.2. Restraints
    • 5.1.2.1. Potential risk of product recall in Cardiac POC testing devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Implementation of unique & new troponin-based test
    • 5.1.3.2. Positive investment and startup ecosystem
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations and concerns associated with the accuracy of cardiac POC testing devices
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Favorable regulatory approvals for various cardiac POC testing devices
  • 5.2.2. Device Type: Exploration of wearable POC devices to provide convenient homecare for managing heart conditions
  • 5.2.3. Application: Critical role played by effective diagnostics & screening procedures in the management of cardiac diseases
  • 5.2.4. End-User: Extensive and comprehensive care provided by hospitals for improving cardiac health
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cardiac POC Testing Devices Market, by Product

• 6.1. Introduction
• 6.2. Cardiac Biomarker Test
  • 6.2.1. B-Type Natriuretic Peptide
  • 6.2.2. Creatine Kinase-MB [CK-MB] Fraction
  • 6.2.3. D-dimer Tests
  • 6.2.4. Myoglobin Tests
  • 6.2.5. Troponin Tests
• 6.3. Consumable & Accessories
• 6.4. Devices
  • 6.4.1. Analyzers
  • 6.4.2. Imaging & Monitoring Devices

7. Cardiac POC Testing Devices Market, by Device Type

• 7.1. Introduction
• 7.2. Bench-top POC Devices
• 7.3. Handheld POC Devices
• 7.4. Wearable POC Devices

8. Cardiac POC Testing Devices Market, by Application

• 8.1. Introduction
• 8.2. Diagnostics & Screening
• 8.3. Monitoring

9. Cardiac POC Testing Devices Market, by End-User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Diagnostic Laboratories
• 9.4. Home Settings
• 9.5. Hospitals

10. Americas Cardiac POC Testing Devices Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cardiac POC Testing Devices Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cardiac POC Testing Devices Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Siemens Healthineers launches NT-proBNPII assay on Atellica platform to enhance heart failure diagnosis and speed patient care
  • 13.3.2. F. Hoffmann-La Roche AG launches NT-proBNP point-of-care test on cobas h 232 to enhance early detection and management of CVD and heart failure in diabetes patients
  • 13.3.3. Analytics for Life and CorVista Health receive FDA clearance for non-invasive CorVista System with Pulmonary Hypertension
  • 13.3.4. Eko Health, Inc. and Mayo Clinic secure FDA clearance for AI-driven low ejection fraction detection
  • 13.3.5. SpinChip Diagnostics receives NOK 115 million investment from bioMerieux to commercialize next-generation cardiac POC testing devices
  • 13.3.6. Roche to acquire LumiraDx's microfluidic point-of-care technology to advance cardiovascular diagnostics
  • 13.3.7. Primary Healthtech's Mobilab device offers early detection of heart and chronic diseases with IoT integration
  • 13.3.8. EDX Medical Group Plc. acquires Hutano Diagnostics Ltd. to develop advanced smartphone-integrated POC tests
  • 13.3.9. EDX Medical Group acquires Hutano Diagnostics to revolutionize rapid healthcare tests with advanced diagnostic technology enhancing speed, accuracy, and cost-effectiveness
  • 13.3.10. Cipla launches cippoint, POC testing device to expand diagnostics portfolio with CE IVD approval, enhancing rapid clinical decision-making and market penetration
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. F. Hoffmann-La Roche Ltd.
  • 13.4.2. Siemens Healthineers AG
  • 13.4.3. Abbott Laboratories
  • 13.4.4. Danaher Corporation
  • 13.4.5. Werfen, S.A.

Companies Mentioned

• 1. Abbott Laboratories
• 2. ACON Laboratories, Inc.
• 3. Alfa Scientific Designs, Inc.
• 4. Bio-Rad Laboratories, Inc.
• 5. Cipla Limited
• 6. Compagnie Merieux Alliance SAS
• 7. Danaher Corporation
• 8. F. Hoffmann-La Roche Ltd
• 9. Getein Biotech, Inc.
• 10. Laboratory Corporation of America Holdings
• 11. LifeSign LLC
• 12. Medtronic plc
• 13. Merck KGaA
• 14. Nano-Ditech Corp.
• 15. Nexus Dx, Inc.
• 16. Nova Biomedical Corporation
• 17. Polymer Technology Systems, Inc. by Sinocare
• 18. Precision Biosensor, Inc.
• 19. QuidelOrtho Corporation
• 20. Sekisui Chemical Co., Ltd.
• 21. Siemens Healthineers AG
• 22. Werfen, S.A.